Bionoid Pharma, Inc. Confirms Name Change to AI Maverick Intel, Inc. Following Delaware Approval
Rhea-AI Summary
Bionoid Pharma (OTC:BINP) has received approval from Delaware for its name change to AI Maverick Intel, effective April 30, 2025. The company has initiated the FINRA process to update its name and trading symbol on OTC Markets. This rebranding reflects the company's strategic pivot towards leveraging artificial intelligence for acquiring and growing technology-driven businesses, particularly in AI, biotech, and digital health sectors.
Positive
- Strategic repositioning towards high-growth AI and technology sectors
- Potential for new business opportunities in AI, biotech, and digital health
Negative
- Significant shift from original pharmaceutical focus may create business uncertainty
- Pending FINRA approval adds regulatory uncertainty to the rebranding process
News Market Reaction 1 Alert
On the day this news was published, BINP declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Company Has Initiated FINRA Process to Complete Rebranding and Ticker Update
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bionoid Pharma, Inc. (OTC PINK:BINP) ("Bionoid" or the "Company") is pleased to confirm that, following the previously announced rebranding initiative, the State of Delaware has approved the Company's formal name change to AI Maverick Intel, Inc., effective April 30, 2025. The Company has submitted the necessary filings with FINRA to update its name and trading symbol on the OTC Markets.
Subject to FINRA's approval, the name and symbol change will be reflected in market listings and all future communications. This step marks the continued execution of the Company's new strategic direction, which centers on leveraging artificial intelligence to acquire, integrate, and grow technology-driven businesses.
"This milestone moves us one step closer to fully implementing the AI Maverick vision," said Wayne Cockburn, CEO. "As we align our public identity with our operational focus, we're unlocking new opportunities to scale our platform and partner with innovators across AI, biotech, and digital health. Our shareholders can expect a bold, tech-forward approach to growth."
About AI Maverick Intel, Inc.
AI Maverick Intel, Inc. is a growth-oriented AI company focused on acquiring and enhancing revenue-generating businesses through its proprietary AI Maverick platform. The technology enables intelligent, two-way communication and data-driven engagement across healthcare, biotech, and other sectors. AI Maverick Intel aims to deliver long-term value through innovation, efficiency, and strategic partnerships.
Stay Connected:
Website | AI Maverick | OTC:BINP | X: @BionoidPharminc
Media Contact:
Wayne Cockburn, CEO
(905) 505-0770
Email: bionoidpharma@gmail.com
SOURCE: AI Maverick Intel, Inc.
View the original press release on ACCESS Newswire
FAQ
Why is Bionoid Pharma (BINP) changing its name to AI Maverick Intel?
When will BINP stock ticker change after the company name change?
What is the effective date of Bionoid Pharma's name change to AI Maverick Intel?
What sectors will AI Maverick Intel (formerly BINP) focus on?
